Inside the ESG Efforts of Leading Biopharma Companies
Despite the fact that the pharmaceutical industry’s focus on Environment, Social and Governance (ESG) has been ahead of its time, its carbon footprint is 55% higher than the automotive industry. Strict regulations and raw material shortages during COVID made it even harder for companies to achieve their sustainability goals. Pharma execs have now realized the only way to drive real change is to develop a continually evolving ESG plan that includes partners and contractors.
And, to implement change one must first assess every step in the manufacturing supply chain – from how ingredients are sourced to energy use and fuel consumption to waste generation. With this baseline ESG data, quick, small changes – that add up to big results – can be made internally and with your partners. Download the playbook to learn more, including:
Sustainability challenges faced by the pharma industry
Why measuring ESG levels is the first step to implementing change
Best practices to create a more sustainable supply chain